173 related articles for article (PubMed ID: 38013388)
1. Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD.
Roberts JC; Christopherson PA; Tarantino MD; Gonzales SE; Morateck PA; Perry CL; Flood VH; Abshire TC; Montgomery RR;
Haemophilia; 2024 Jan; 30(1):161-168. PubMed ID: 38013388
[TBL] [Abstract][Full Text] [Related]
2. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.
Flood VH; Gill JC; Morateck PA; Christopherson PA; Friedman KD; Haberichter SL; Hoffmann RG; Montgomery RR
Blood; 2011 Feb; 117(6):e67-74. PubMed ID: 21148813
[TBL] [Abstract][Full Text] [Related]
3. Clinical and laboratory phenotype variability in type 2M von Willebrand disease.
Doruelo AL; Haberichter SL; Christopherson PA; Boggio LN; Gupta S; Lentz SR; Shapiro AD; Montgomery RR; Flood VH
J Thromb Haemost; 2017 Aug; 15(8):1559-1566. PubMed ID: 28544236
[TBL] [Abstract][Full Text] [Related]
4. Evaluating Performance of Contemporary and Historical von Willebrand Factor (VWF) Assays in the Laboratory Identification of von Willebrand Disease (VWD): The Australasian Experience.
Favaloro EJ; Dean E; Arunachalam S
Semin Thromb Hemost; 2022 Sep; 48(6):711-731. PubMed ID: 35803263
[TBL] [Abstract][Full Text] [Related]
5. A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.
Rauch A; Caron C; Vincent F; Jeanpierre E; Ternisien C; Boisseau P; Zawadzki C; Fressinaud E; Borel-Derlon A; Hermoire S; Paris C; Lavenu-Bombled C; Veyradier A; Ung A; Vincentelli A; van Belle E; Lenting PJ; Goudemand J; Susen S
Thromb Haemost; 2016 May; 115(5):950-9. PubMed ID: 26791163
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test.
Michiels JJ; Smejkal P; Penka M; Batorova A; Pricangova T; Budde U; Vangenechten I; Gadisseur A
Clin Appl Thromb Hemost; 2017 Sep; 23(6):518-531. PubMed ID: 27443694
[TBL] [Abstract][Full Text] [Related]
7. Rapid discrimination of the phenotypic variants of von Willebrand disease.
Roberts JC; Morateck PA; Christopherson PA; Yan K; Hoffmann RG; Gill JC; Montgomery RR;
Blood; 2016 May; 127(20):2472-80. PubMed ID: 26917779
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease.
Favaloro EJ
Thromb Haemost; 2010 Nov; 104(5):1009-21. PubMed ID: 20806123
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease.
Favaloro EJ; Mohammed S
Thromb Res; 2016 May; 141():202-11. PubMed ID: 26743192
[TBL] [Abstract][Full Text] [Related]
10. Von Willebrand disease type 2M: Correlation between genotype and phenotype.
Maas DPMSM; Atiq F; Blijlevens NMA; Brons PPT; Krouwel S; Laros-van Gorkom BAP; Leebeek FWG; Nieuwenhuizen L; Schoormans SCM; Simons A; Meijer D; van Heerde WL; Schols SEM
J Thromb Haemost; 2022 Feb; 20(2):316-327. PubMed ID: 34758185
[TBL] [Abstract][Full Text] [Related]
11. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
Dean JA; Blanchette VS; Carcao MD; Stain AM; Sparling CR; Siekmann J; Turecek PL; Lillicrap D; Rand ML
Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962
[TBL] [Abstract][Full Text] [Related]
12. CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease.
Sanders YV; van der Bom JG; Isaacs A; Cnossen MH; de Maat MP; Laros-van Gorkom BA; Fijnvandraat K; Meijer K; van Duijn CM; Mauser-Bunschoten EP; Eikenboom J; Leebeek FW;
J Thromb Haemost; 2015 Jun; 13(6):956-66. PubMed ID: 25832887
[TBL] [Abstract][Full Text] [Related]
13. von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis.
Kalot MA; Husainat N; El Alayli A; Abughanimeh O; Diab O; Tayiem S; Madoukh B; Dimassi AB; Qureini A; Ameer B; Eikenboom JCJ; Giraud N; McLintock C; McRae S; Montgomery RR; O'Donnell JS; Scappe N; Sidonio RF; Brignardello-Petersen R; Flood VH; Connell NT; James PD; Mustafa RA
Blood Adv; 2022 Jan; 6(1):62-71. PubMed ID: 34610118
[TBL] [Abstract][Full Text] [Related]
14. Type 2M von Willebrand disease - more often misidentified than correctly identified.
Favaloro EJ; Bonar RA; Mohammed S; Arbelaez A; Niemann J; Freney R; Meiring M; Sioufi J; Marsden K
Haemophilia; 2016 May; 22(3):e145-55. PubMed ID: 27029718
[TBL] [Abstract][Full Text] [Related]
15. How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types.
Favaloro EJ; Mohammed S; Vong R; Oliver S; Brennan Y; Favaloro JW; Curnow J
Haemophilia; 2021 Jan; 27(1):137-148. PubMed ID: 33215808
[TBL] [Abstract][Full Text] [Related]
16. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.
Flood VH; Christopherson PA; Gill JC; Friedman KD; Haberichter SL; Bellissimo DB; Udani RA; Dasgupta M; Hoffmann RG; Ragni MV; Shapiro AD; Lusher JM; Lentz SR; Abshire TC; Leissinger C; Hoots WK; Manco-Johnson MJ; Gruppo RA; Boggio LN; Montgomery KT; Goodeve AC; James PD; Lillicrap D; Peake IR; Montgomery RR
Blood; 2016 May; 127(20):2481-8. PubMed ID: 26862110
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a fully automated von Willebrand factor assay panel for the diagnosis of von Willebrand disease.
Stufano F; Baronciani L; Bucciarelli P; Boscarino M; Colpani P; Pagliari MT; Peyvandi F
Haemophilia; 2020 Mar; 26(2):298-305. PubMed ID: 32107842
[TBL] [Abstract][Full Text] [Related]
18. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
19. Quantitative impact of using different criteria for the laboratory diagnosis of type 1 von Willebrand disease.
Quiroga T; Goycoolea M; Belmont S; Panes O; Aranda E; Zúñiga P; Pereira J; Mezzano D
J Thromb Haemost; 2014 Aug; 12(8):1238-43. PubMed ID: 24796601
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of slightly reduced von Willebrand factor activity.
Bykowska K; Ceglarek B
Pol Arch Intern Med; 2020 Mar; 130(3):225-231. PubMed ID: 31990275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
